The stock of Dianthus Therapeutics Inc (DNTH) has gone down by -26.50% for the week, with a -20.50% drop in the past month and a -27.73% drop in the past quarter. The volatility ratio for the week is 12.83%, and the volatility levels for the past 30 days are 7.97% for DNTH. The simple moving average for the past 20 days is -15.61% for DNTH’s stock, with a -23.06% simple moving average for the past 200 days.
Is It Worth Investing in Dianthus Therapeutics Inc (NASDAQ: DNTH) Right Now?
The 36-month beta value for DNTH is also noteworthy at 1.71. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for DNTH is 19.23M, and at present, short sellers hold a 31.22% of that float. The average trading volume of DNTH on January 15, 2025 was 247.29K shares.
DNTH) stock’s latest price update
Dianthus Therapeutics Inc (NASDAQ: DNTH)’s stock price has gone decline by -13.74 in comparison to its previous close of 23.04, however, the company has experienced a -26.50% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-01-08 that NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at the 43rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco.
Analysts’ Opinion of DNTH
Oppenheimer, on the other hand, stated in their research note that they expect to see DNTH reach a price target of $48. The rating they have provided for DNTH stocks is “Outperform” according to the report published on October 03rd, 2024.
Robert W. Baird gave a rating of “Outperform” to DNTH, setting the target price at $58 in the report published on July 26th of the previous year.
DNTH Trading at -19.13% from the 50-Day Moving Average
After a stumble in the market that brought DNTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.15% of loss for the given period.
Volatility was left at 7.97%, however, over the last 30 days, the volatility rate increased by 12.83%, as shares sank -15.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.92% lower at present.
During the last 5 trading sessions, DNTH fell by -26.50%, which changed the moving average for the period of 200-days by -35.05% in comparison to the 20-day moving average, which settled at $23.55. In addition, Dianthus Therapeutics Inc saw -8.83% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for DNTH
Current profitability levels for the company are sitting at:
- -15.45 for the present operating margin
- 0.94 for the gross margin
The net margin for Dianthus Therapeutics Inc stands at -12.5. The total capital return value is set at -0.24. Equity return is now at value -25.99, with -24.54 for asset returns.
Based on Dianthus Therapeutics Inc (DNTH), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -160.5.
Currently, EBITDA for the company is -48.17 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of 103.41. The receivables turnover for the company is 4.15for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.30.
Conclusion
In summary, Dianthus Therapeutics Inc (DNTH) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
